https://orcid.org/0000-0003-0101-2137
![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
ABSTRACT
Guillain-Barré syndrome (GBS) is an acute inflammatory polyradiculoneuropathy. In two-thirds of patients, it is preceded by an upper respiratory or gastrointestinal tract infection. Temporally associated cases of GBS following COVID-19 vaccination have been described with different COVID-19 vaccines. In this study, we report three cases of GBS patients following COVID-19 vaccine. Two of the studied patients received the Sinopharm vaccine and one patient received the AstraZeneca vaccine. All patients were diagnosed with acute motor axonal neuropathy (AMAN) type of GBS, on nerve conduction studies. All three patients responded well to treatment with intravenous immunoglobulin (IVIg). The association between COVID-19 vaccination and GBS is not well understood and more studies are needed to establish whether it is merely an association or a causal relationship.
Abbreviations
| GBS | = | Guillain-Barré syndrome |
| MRC | = | Medical Research Council |
| CSF | = | cerebrospinal fluid |
| NP | = | nasopharyngeal |
| RT-PCR | = | real time polymerase chain reaction |
| EMG-NCS | = | electromyography and nerve conduction studies |
| AMAN | = | acute motor axonal neuropathy |
| IVIG | = | intravenous immunoglobulin |
| AIDP | = | acute inflammatory demyelinating polyradiculoneuropathy |
Disclosure statement
No potential conflict of interest was reported by the author(s).